Kronos Bio, Inc. (KRON)

Kronos Bio, Inc. (KRON) Healthcare & Pipeline Overview

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Mateo, California, specializing in novel cancer therapeutics. The company's product engine targets dysregulated transcription factors, advancing lead candidates like entospletinib for acute myeloid leukemia and KB-0742 for MYC-amplified solid tumors, aiming to address significant unmet medical needs in oncology.

What Is the Investment Thesis for KRON?

Kronos Bio, Inc. presents an investment thesis centered on its clinical-stage pipeline targeting novel mechanisms in oncology, specifically dysregulated transcription factors. The company's lead candidate, entospletinib (ENTO), is poised for a registrational Phase 3 trial in NPM1-mutated acute myeloid leukemia, a patient population with significant unmet needs. Successful progression and regulatory approval of ENTO could unlock substantial market potential, given the high incidence and severity of AML. Additionally, KB-0742, in Phase 1/2 for MYC-amplified solid tumors, addresses another critical oncogenic pathway with broad applicability. The company's current market capitalization of $53.65M reflects its early-stage nature and offers potential for significant upside if clinical milestones are met. While operating with a negative profit margin of -826.7% typical of R&D-intensive biotech, its reported gross margin of 91.6% indicates strong pricing power potential for future commercialized products. The high beta of 1.64 suggests sensitivity to market movements, characteristic of clinical-stage biotechnology firms, appealing to investors seeking higher risk-reward profiles in the oncology space.

Based on FMP financials and quantitative analysis

KRON Key Highlights

• Kronos Bio, Inc. maintains a gross margin of 91.6%, indicating strong potential profitability for any successfully commercialized therapies.
• The company operates with a market capitalization of $53.65M, reflecting its early-stage development and potential for significant growth upon clinical success.
• Kronos Bio reported a profit margin of -826.7%, which is typical for a clinical-stage biopharmaceutical company heavily investing in research and development.
• The company's stock exhibits a Beta of 1.64, suggesting higher volatility compared to the broader market, characteristic of the biotechnology sector.
• Kronos Bio is advancing entospletinib into a planned registrational Phase 3 clinical trial for acute myeloid leukemia, representing a key pipeline milestone.

Who Are KRON's Competitors?

KRON is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KRON's Key Strengths?

• Focused pipeline with two distinct clinical-stage oncology candidates targeting specific, high-need patient populations.
• Proprietary product engine centered on dysregulated transcription factors, offering a differentiated scientific approach.
• Lead candidate, entospletinib, is advancing to a registrational Phase 3 trial, indicating significant progress.
• High gross margin of 91.6% suggests strong potential profitability for future commercialized products.

What Are KRON's Weaknesses?

• Operating with a significant negative profit margin (-826.7%), typical for clinical-stage biotech, but indicating reliance on external funding.
• Small employee base of 8, which may limit the scope and speed of parallel development efforts without partnerships.
• High beta (1.64) indicates stock price volatility, which can be a concern for some investors.
• No currently commercialized products, meaning no revenue generation from drug sales at present.

What Could Drive KRON Stock Higher?

• Initiation of the registrational Phase 3 clinical trial for entospletinib (ENTO) in combination with induction chemotherapy for acute myeloid leukemia patients with NPM1 mutations.
• Progression and data readouts from the Phase 1/2 clinical trial of KB-0742 for the treatment of MYC-amplified solid tumors.
• Announcement of strategic partnerships or collaborations that could provide non-dilutive funding or expand development capabilities for pipeline assets.

What Are the Key Risks for KRON?

• Financial-distress signal — its Altman Z-Score of -7.09 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-69.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of entospletinib (ENTO) to meet primary endpoints in its planned registrational Phase 3 clinical trial, which would significantly impact its commercial viability.
• Clinical development risks associated with KB-0742, including potential safety concerns or lack of efficacy observed in its ongoing Phase 1/2 trial.
• Significant capital requirements for ongoing research and development, potentially leading to future equity dilution for existing shareholders.
• Intense competition within the oncology therapeutic market from larger pharmaceutical companies and other biotechnology firms with established pipelines and resources.

What Are the Growth Opportunities for KRON?

• Growth opportunity 1: Advancement of Entospletinib (ENTO) in Acute Myeloid Leukemia (AML). The planned registrational Phase 3 clinical trial for ENTO in NPM1-mutated AML represents a critical near-to-mid-term growth driver. AML, particularly with NPM1 mutations, is a severe hematologic malignancy with high unmet needs. Successful completion of this trial and subsequent regulatory approval could position ENTO as a significant new treatment option, potentially addressing a market segment valued in the billions globally. The oral administration of ENTO could also offer a patient-friendly alternative to existing therapies, enhancing its market adoption and commercial potential within the next 3-5 years.
• Growth opportunity 2: Development of KB-0742 for MYC-amplified Solid Tumors. KB-0742, an orally bioavailable CDK9 inhibitor, is currently in Phase 1/2 clinical trials for MYC-amplified solid tumors. MYC amplification is a prevalent oncogenic driver across a wide range of aggressive cancers, including lung, breast, and colon cancers, representing a substantial patient population. The successful progression of KB-0742 through clinical development could unlock access to a multi-billion dollar market for solid tumor therapeutics. Its broad applicability could diversify Kronos Bio's pipeline beyond hematologic malignancies, offering significant long-term growth potential over the next 5-10 years.
• Growth opportunity 3: Expansion of the Product Engine Targeting Dysregulated Transcription Factors. Kronos Bio's proprietary product engine, focused on dysregulated transcription factors and transcriptional regulatory networks, represents a foundational growth opportunity. This platform allows for the discovery and development of additional novel drug candidates beyond ENTO and KB-0742. By continuously identifying new targets and developing therapies that modulate these fundamental oncogenic pathways, the company can build a robust pipeline. This strategic focus could lead to a sustained stream of innovative oncology treatments, creating long-term value and addressing diverse cancer indications over the next decade and beyond.
• Growth opportunity 4: Potential for Strategic Partnerships and Collaborations. As a clinical-stage biopharmaceutical company with a focused pipeline, Kronos Bio has the opportunity to engage in strategic partnerships, licensing agreements, or collaborations with larger pharmaceutical companies. Such alliances could provide non-dilutive funding, leverage broader development and commercialization expertise, and accelerate the market reach of its product candidates. Partnerships could also validate Kronos Bio's scientific platform and pipeline, potentially leading to significant upfront payments, milestone payments, and royalties, thereby bolstering its financial position and expanding its therapeutic impact globally within the next 2-7 years.
• Growth opportunity 5: Addressing Unmet Medical Needs in Oncology. Kronos Bio's strategy is inherently tied to addressing significant unmet medical needs in oncology, particularly in specific patient populations like NPM1-mutated AML and MYC-amplified solid tumors. By developing targeted therapies for these challenging indications, the company positions itself to capture market share where existing treatments are insufficient or non-existent. The focus on novel mechanisms of action provides a competitive edge, potentially leading to breakthrough designations and accelerated approval pathways. This commitment to high-need areas can drive strong demand and premium pricing for successful products, fostering sustainable growth over the next 5-10 years.

What Opportunities Does KRON Have?

• Successful clinical development and regulatory approval of entospletinib could address a significant unmet need in NPM1-mutated AML.
• Expansion of KB-0742's potential into various MYC-amplified solid tumors could unlock a broad market.
• Potential for strategic partnerships or licensing agreements to accelerate development and commercialization efforts.
• Leveraging the product engine to discover and advance additional novel oncology candidates.

What Threats Does KRON Face?

• High risk of clinical trial failures, which could significantly impact the company's valuation and future prospects.
• Intense competition from other pharmaceutical and biotechnology companies developing cancer therapeutics.
• Stringent regulatory approval processes and potential delays from health authorities.
• Need for substantial ongoing funding to support R&D and clinical trials, leading to potential shareholder dilution.

What Are KRON's Competitive Advantages?

• Proprietary product engine focused on dysregulated transcription factors, offering a unique approach to cancer therapy.
• Novel drug candidates like entospletinib and KB-0742 targeting specific oncogenic pathways.
• Intellectual property protection surrounding its drug candidates and therapeutic approaches.
• Specialized scientific expertise in transcriptional regulation and cancer biology.

What Does KRON Do?

Kronos Bio, Inc., established in 2017 and headquartered in San Mateo, California, operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative cancer therapeutics. The company's core scientific approach centers on its proprietary product engine, which is designed to identify and modulate dysregulated transcription factors and the complex transcriptional regulatory networks that drive oncogenic activity. This foundational strategy aims to address the root causes of various cancers by interfering with the genetic programs that promote tumor growth and survival. The company's pipeline features two primary product candidates. Its lead candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor. ENTO is currently slated for a registrational Phase 3 clinical trial, where it will be evaluated in combination with induction chemotherapy for acute myeloid leukemia (AML) patients who harbor NPM1 mutations. This represents a significant step towards potentially offering a new treatment option for a challenging patient population within AML. In parallel, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9). KB-0742 is being developed for the treatment of MYC-amplified solid tumors and is currently undergoing a Phase 1/2 clinical trial. MYC amplification is a common oncogenic driver in many aggressive solid tumors, indicating a broad potential application for this therapy. By focusing on these distinct yet critical pathways in cancer biology, Kronos Bio aims to develop targeted therapies that can provide meaningful clinical benefits to patients with high unmet medical needs. The company's evolution since its incorporation has been marked by its commitment to leveraging deep biological insights into transcriptional regulation to build a promising oncology pipeline.

What Products and Services Does KRON Offer?

• Discover and develop novel cancer therapeutics.
• Focus on dysregulated transcription factors and their regulatory networks.
• Advance entospletinib (ENTO), a selective spleen tyrosine kinase inhibitor, for acute myeloid leukemia (AML).
• Prepare ENTO for a registrational Phase 3 clinical trial in NPM1-mutated AML patients.
• Develop KB-0742, a cyclin dependent kinase 9 inhibitor, for MYC-amplified solid tumors.
• Conduct a Phase 1/2 clinical trial for KB-0742.
• Utilize a proprietary product engine to identify and modulate oncogenic activity.
• Headquartered in San Mateo, California, and incorporated in 2017.

How Does KRON Make Money?

• Primarily focused on research and development of novel drug candidates for oncology.
• Aims to generate future revenue through the successful clinical development, regulatory approval, and commercialization of its proprietary therapeutics.
• Potential for licensing agreements or strategic partnerships with larger pharmaceutical companies for co-development or commercialization.
• Relies on capital raises and investments to fund ongoing clinical trials and R&D activities.

What Industry Does KRON Operate In?

Kronos Bio, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology therapeutics. This sector is characterized by intense research and development, lengthy clinical trial processes, and significant regulatory hurdles. The broader healthcare market continues to see robust demand for novel cancer treatments, driven by increasing cancer incidence and advancements in understanding disease biology. Kronos Bio distinguishes itself by targeting dysregulated transcription factors and their associated regulatory networks, a mechanism that holds promise for addressing cancers resistant to conventional therapies. The competitive landscape includes numerous pharmaceutical giants and smaller biotech firms, all vying for market share in various oncology indications. Kronos Bio's positioning as a clinical-stage company means its current focus is on advancing its pipeline through trials, aiming to carve out a niche in specific leukemia and solid tumor markets by offering differentiated therapeutic approaches.

Who Are KRON's Key Customers?

• Future customers will include oncologists and hematologists prescribing treatments for cancer patients.
• Hospitals and cancer treatment centers administering the therapies.
• Patients diagnosed with acute myeloid leukemia (AML), particularly those with NPM1 mutations.
• Patients with MYC-amplified solid tumors, pending clinical development and regulatory approvals.

Company Profile

Kronos Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Mateo, US. The company is led by CEO Deborah A. Knobelman. KRON has traded publicly since 2020.

F-Score 3/9Financial Health

Kronos Bio, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.09 places it in the distress zone, a signal of elevated financial risk.

ROE -70%Key Financial Metrics

Return on equity for Kronos Bio, Inc. stands at -69.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -69.2%, showing how much profit it generates from its asset base. A current ratio of 7.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -162.8%, the inverse of the P/E and a quick read on earnings relative to price.

KRON Valuation & Market Position

With a $53.65M market cap, Kronos Bio, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KRON's quantitative score of 65/100 is below the peer average of 78/100.

FY2026 estForward Outlook

Wall Street analysts project Kronos Bio, Inc. revenue of about $12.8M for fiscal 2026, with EPS near $-1.35.

KRON Financials

KRON Latest News

KRON Analyst Consensus

KRON MoonshotScore

KRON Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources